Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eita Fujimoto
Observed names:
E. Fujimoto,
Eita FUJIMOTO,
Fujimoto, Eita
Institution:
Fujimoto Dental and Oral Surgery Clinic
Observed institutions:
National Defense Medical College Hospital,
Fujimoto Dental and Oral Surgery Clinic,
Chiba Hokusou Hospital,
National Defense Medical College,
Nippon Medical School
ORCID:
0009-0002-5914-3244
Observed ORCID:
0009-0002-5914-3244
OpenAlex ID:
A5039773339
Nε-(Carboxymethyl)lysine Modification of Elastin Alters Its Biological Properties: Implications for the Accumulation of Abnormal Elastic Fibers in Actinic Elastosis
2011
·
Eiji Yoshinaga
, Akira Kawada
, et al.
·
Journal of Investigative Dermatology
·
61
PDF
Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan
2023
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
The Journal of Dermatology
·
57
AGE-Modified Collagens I and III Induce Keratinocyte Terminal Differentiation through AGE Receptor CD36: Epidermal–Dermal Interaction in Acquired Perforating Dermatosis
2009
·
Eita Fujimoto
, Takashi Kobayashi
, et al.
·
Journal of Investigative Dermatology
·
51
PDF
Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan
2024
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
Journal of Dermatological Treatment
·
41
PDF
Real‐world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single‐center retrospective study
2024
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
The Journal of Dermatology
·
40
PDF
Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
2023
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
Journal of Clinical Medicine
·
39
PDF
The Eosinophil-to-Lymphocyte Ratio Acts as an Indicator for Improvement of Clinical Signs and Itch by Upadacitinib Treatment in Atopic Dermatitis
2023
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
Journal of Clinical Medicine
·
38
PDF
Leukocytapheresis treatment for pyoderma gangrenosum
2004
·
E. Fujimoto
, N. Fujimoto
, et al.
·
British Journal of Dermatology
·
37
Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks
2024
·
Teppei Hagino
, Risa Hamada
, et al.
·
Frontiers in Immunology
·
33
The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis
2023
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
Journal of Dermatological Treatment
·
31
PDF
Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: A 24‐week real‐world study
2024
·
Teppei Hagino
, Marina Onda
, et al.
·
The Journal of Dermatology
·
30
Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
2023
·
Teppei Hagino
, Mai Yoshida
, et al.
·
Journal of Dermatological Treatment
·
30
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
2024
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
Journal of Dermatological Treatment
·
29
PDF
Effects and cost of glycyrrhizin in the treatment of upper respiratory tract infections in members of the Japanese maritime self-defense force: Preliminary report of a prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment clinical trial
2004
·
Youichi Yanagawa
, Masatsune Ogura
, et al.
·
Current Therapeutic Research
·
28
PDF
A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patients
2025
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
Journal of the American Academy of Dermatology
·
27
PDF
Effectiveness of long‐term bimekizumab treatment and predictive factors for responders in moderate‐to‐severe psoriasis: A 52‐week real‐world study
2024
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
The Journal of Dermatology
·
27
PDF
Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
2023
·
Teppei Hagino
, Risa Hamada
, et al.
·
Clinical Cosmetic and Investigational Dermatology
·
27
PDF
Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate‐to‐severe atopic dermatitis
2023
·
Teppei Hagino
, Mai Yoshida
, et al.
·
The Journal of Dermatology
·
26
PDF
Reciprocal regulation of LOX and LOXL2 expression during cell adhesion and terminal differentiation in epidermal keratinocytes
2009
·
Eita Fujimoto
, Shingo Tajima
·
Journal of Dermatological Science
·
26
Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study
2024
·
Teppei Hagino
, Marina Onda
, et al.
·
Clinical and Experimental Dermatology
·
25
Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study
2024
·
Teppei Hagino
, Marina Onda
, et al.
·
Dermatitis
·
24
Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
2024
·
Teppei Hagino
, Mai Yoshida
, et al.
·
Journal of Dermatological Treatment
·
23
Galectin‐7 and actin are components of amyloid deposit of localized cutaneous amyloidosis
2012
·
Yoshinori Miura
, Satoru Harumiya
, et al.
·
Experimental Dermatology
·
23
Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions
2024
·
Teppei Hagino
, Hidehisa Saeki
, et al.
·
Clinical and Experimental Dermatology
·
22
Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan
2025
·
Teppei Hagino
, Akihiko Uchiyama
, et al.
·
Dermatitis
·
21
Show more works
View as search
Works count:
111
Citation count:
1,156
H-index:
23
I10-index:
39
Year
Topic
Type
